Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital;Avaliação dos efeitos colaterais da nevirapina em gestantes HIV positivo em Hospital Universitário do sul do Brasil

Revista Brasileira de Ginecologia e Obstetricia

Volumn 30, Issue 1, 2008, Pages 19-24

  Kondo, William ^a,b   De Astori, Adriane De Assis Fischer ^a   Gomes, Suria El Kouba ^a   Fernandes, Rachelle De Brito ^a   Sasaki, Maria Das Graças ^a   Sbalqueiro, Renato Luiz ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b NONE   (Brazil)

Author keywords

HIV infections drug therapy; HIV 1; Liver diseases chemically induced; Nevirapine adverse effects; Nevirapine toxicity; Pregnancy complications, infections

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREGNANCY; PREGNANCY COMPLICATION; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BRAZIL; FEMALE; HIV INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 42149089828     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-72032008000100004     Document Type: Article

References (25)

1. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36(3):772-6.
2. Lyons F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med. 2006;7(4):255-60.
3. Joy S, Poi M, Hughes L, Brady MT, Koletar SL, Para MF, et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol. 2005;106(5 Pt 1):1032-8.
4. João EC, Calvet GA, Menezes JA, D'Ippolito MM, Cruz ML, Salgado LA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol. 2006;194(1):199-202.
5. Brasil - Ministério da Saúde. Recomendações para profilaxia da transmissão vertical do HIV e terapia anti-retroviral em gestantes [documento da Internet]. Brasília: 2006 [citado 18 dez 2007]. Disponível em: http://www.saude.rio.rj.gov.br/media/ dstaids_consenso_gestante_2006.pdf
6. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795-802.
7. de Maat MM, ter Heine R, van Gorp EC, Mulder JW, Mairuhu AT, Beijnen JH. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS. 2003;17(15):2209-14.
8. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Hamrick HJ Jr, Powderly WG, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001;32(1):124-9.
9. Martín-Carbonero L, Núñez M, González-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4(2):115-20.
10. Brasil - Ministério da Saúde [documento da Internet]. Protocolo para a prevenção de transmissão vertical de HIV e sífilis. Brasília: 2006 [citado 18 dez 2007]. Disponível em: http://www.saude.rio.rj.gov.br/media/dstaids_gestante_protocolo_out06.pdf
11. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173-80.
12. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341(6):394-402.
13. Clarke JR, Braganza R, Mirza A, Stainsby C, Ait-Khaled M, Wright A, et al. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol. 1999;59(3):364-8.
14. Saba J. The results of the PETRA intervention trial to prevent perinatal transmission in sub-Saharan Africa. Abstract of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, USA. Alexandria: Foundation for Retrovirology and Human Health; 1999. p. S6.
15. McGowan JP, Shah SS. Management of HIV infection during pregnancy. Curr Opin Obstet Gynecol. 2000;12(5):357-67.
16. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356(9239):1423-30.
17. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS. 2005;19(2):185-92.
18. Ho TT, Wong KH, Chan KC, Lee SS. High incidence of nevirapine-associated rash in HIV-infected Chinese. AIDS. 1998;12(15):2082-3.
19. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34 Suppl 1:S21-33.
20. Núñez M, Lana R, Mendoza JL, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27(5):426-31.
21. Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007;44(4):371-6.
22. Wooltorton E. HIV drug nevirapine (Viramune): risk of severe hepatotoxicity. CMAJ. 2004;170(7):1091.
23. Kramer F, Stek A, Du WB, Kovacs A. Nevirapine tolerability in HIV-infected women in pregnancy. Abstract of the 11th Conference on Retrovirus and Opportunistic Infections; Feb 2004; San Francisco, USA. Alexandria: Foundation for Retrovirology and Human Health; 2004. p. 923.
24. Natarajan U, Pym A, McDonald C, Velisetty P, Edwards SG, Hay P, et al. Safety of nevirapine in pregnancy. HIV Med. 2007;8(1):64-9.
25. Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med. 2006;7(5):338-44.